Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas

[1]  H. Kalofonos,et al.  RANK and EGFR in invasive breast carcinoma. , 2017, Cancer genetics.

[2]  Marion Procter,et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer , 2017, The New England journal of medicine.

[3]  W. Woodward,et al.  Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression , 2017, Breast Cancer Research and Treatment.

[4]  A. Green,et al.  Molecular classification of breast cancer: what the pathologist needs to know. , 2017, Pathology.

[5]  M. Karamouzis,et al.  RANKL Signaling and ErbB Receptors in Breast Carcinogenesis. , 2016, Trends in molecular medicine.

[6]  J. Visvader,et al.  RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers , 2016, Nature Medicine.

[7]  E. Saltzstein,et al.  Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis , 2015, Cancer science.

[8]  C. Denkert,et al.  RANK expression as a prognostic and predictive marker in breast cancer , 2014, Breast Cancer Research and Treatment.

[9]  S. Egan,et al.  Targeting HER2+ breast cancer: the TBK1/IKKε axis , 2014, Oncoscience.

[10]  I. Ellis,et al.  Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay , 2014, Breast Cancer Research and Treatment.

[11]  T. Bowman,et al.  NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth , 2013, Molecular Cancer Research.

[12]  Chia-Hung Chen,et al.  Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors , 2013, BMC Genomics.

[13]  T. Takeda,et al.  Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines , 2013, Journal of experimental & clinical cancer research : CR.

[14]  M. Karin,et al.  A NIK-IKKα module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1. , 2013, Cancer cell.

[15]  M. Beckmann,et al.  HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer , 2013, Breast Care.

[16]  Dafydd G. Thomas,et al.  HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. , 2012, Cancer research.

[17]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[18]  F. Claret,et al.  Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer , 2012, Front. Oncol..

[19]  F. Climent,et al.  RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. , 2012, Cancer research.

[20]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[21]  J. Cheng,et al.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.

[22]  M. Widschwendter,et al.  Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer , 2010, Nature.

[23]  D. Branstetter,et al.  RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis , 2010, Nature.

[24]  A. Baldwin,et al.  Her2 Activates NF-κB and Induces Invasion Through the Canonical Pathway Involving IKKα , 2009, Oncogene.

[25]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[26]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[27]  P. Kostenuik,et al.  Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  Shiyong Li,et al.  NF-κB-Mediated HER2 Overexpression inRadiation-Adaptive Resistance , 2009, Radiation research.

[29]  H. Ryoo,et al.  Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross‐talking with RANK signaling , 2008, Journal of cellular physiology.

[30]  M. Karin,et al.  IκB kinase α kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells , 2007, Proceedings of the National Academy of Sciences.

[31]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[32]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  M. Karin,et al.  IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Karamouzis,et al.  Breast cancer: the upgraded role of HER-3 and HER-4. , 2007, The international journal of biochemistry & cell biology.

[35]  Debajit K. Biswas,et al.  NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis , 2004 .

[36]  Sankar Ghosh,et al.  NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  E. Schmidt,et al.  IKKα Provides an Essential Link between RANK Signaling and Cyclin D1 Expression during Mammary Gland Development , 2001, Cell.

[38]  E. Schmidt,et al.  IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. , 2001, Cell.